Datapoint: Alvotech and Teva Plot Broader Simlandi Launch
Alvotech and Teva Pharmaceutical Industries Ltd. Signed a “long-term agreement” to bring its Simlandi (adalimumab) biosimilar to market with an undisclosed partner, according to press reports. In February, the FDA designated Simlandi as the first biosimilar to be interchangeable with Humira (adalimumab), the best-selling drug from AbbVie that treats a variety of autoimmune conditions. With an interchangeable status, a biosimilar can be substituted for a reference biologic by a pharmacist with a provider’s approval. Simlandi had previously struggled to gain FDA approval, making it a late entrant in the burgeoning Humira biosimilar field. Humira continues to hold covered or better status for 91% of all insured lives under the pharmacy benefit.
SOURCE: MMIT Analytics, as of 4/26/24
